FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 長風藥業股份有限公司 呈交日期： 2026年4月9日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02652 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | 已發行股份總數 | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（ ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 長風藥業股份有限公司 呈交日期： 2026年3月31日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02652 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 ...

Financial Performance - The company reported revenue of approximately RMB 432.52 million for the year ending December 31, 2025, a decrease of 28.8% compared to RMB 607.75 million in 2024[5] - Gross profit for 2025 was RMB 327.94 million, down from RMB 491.37 million in 2024, reflecting a decline of 33.2%[5] - Net profit attributable to shareholders was RMB 2.49 million in 2025, significantly lower than RMB 21.09 million in 2024, marking an 88.2% decrease[5] - Adjusted net profit (non-IFRS measure) was RMB 31.75 million in 2025, down from RMB 51.87 million in 2024, a decline of 38.8%[5] - Revenue decreased by 29.0% from RMB 607.8 million in 2024 to RMB 432.5 million in 2025, primarily due to reduced sales of inhalation products, especially CF017[19] - CF017 sales revenue dropped by 40.0% from RMB 574.5 million in 2024 to RMB 344.7 million in 2025, attributed to pricing pressure and decreased market demand[19] - CF018 sales revenue increased significantly from RMB 23.9 million in 2024 to RMB 79.0 million in 2025, driven by its inclusion in the national medical insurance catalog[20] - Gross profit fell by 33.3% from RMB 491.4 million in 2024 to RMB 327.9 million in 2025, with gross margin declining from 80.9% to 75.8%[22] - The company recorded a profit of RMB 2.5 million, a significant decrease from RMB 21.1 million in 2024[32] - The adjusted profit (non-IFRS measure) for 2025 was RMB 31.8 million, down from RMB 51.9 million in 2024, reflecting a decline of approximately 38.8%[36] Market and Product Development - The company faced multiple pressures in 2025, including a decrease in average selling prices due to VBP updates and a lower incidence of respiratory infections, impacting short-term market demand[7] - CF017, the company's core product, generated revenue of approximately RMB 344.7 million in 2025, down from RMB 574.5 million in 2024, primarily due to changes in VBP terms[9] - CF018, a new product, saw revenue growth from RMB 1.3 million in 2023 to RMB 79.0 million in 2025, indicating strong market acceptance and acceleration post-reimbursement inclusion[10] - The company aims to transition from a single product-driven model to a more diversified revenue structure, focusing on becoming a global inhalation system platform company[8] - The company signed a strategic cooperation agreement with Akang Health in February 2025 to enhance chronic disease management, focusing on respiratory diseases, which will improve prescription handling, drug delivery, patient education, and long-term repurchase[12] - In March 2026, the company entered a strategic partnership with JD Health for the online exclusive launch of multiple new respiratory and nasal products over the next three years, aiming to enhance product launch efficiency and patient accessibility[12] - The nasal spray product family is entering a clearer monetization phase, with new drug clinical trial applications submitted in 2025, including mometasone furoate and levofloxacin nebulizers, and the approval of budesonide nasal spray in January 2026[13] - The company is developing over 20 candidate products for major markets and plans to achieve at least five new product approvals and commercial launches between 2026 and 2030[14] - The inhaled powder candidate drug ICF001 received IND approval in March 2026, targeting pulmonary arterial hypertension and interstitial lung disease-related pulmonary hypertension, with a focus on improving drug delivery and patient experience[15] - The inhaled powder candidate drug ICF004, aimed at treating progressive fibrotic interstitial lung disease, received IND approval in February 2026, demonstrating a differentiated distribution profile in preclinical studies[16] - The company is leading a new inhaled nucleic acid drug development project, focusing on siRNA delivery for respiratory diseases, which has been recognized as a major technological project in Jiangsu Province[17] - The company has developed a comprehensive delivery system for inhaled siRNA candidates, with the goal of creating the world's first approved inhaled siRNA drug for chronic respiratory diseases[17] Financial Position and Assets - The company's property, plant, and equipment increased from RMB 531.1 million as of December 31, 2024, to RMB 547.4 million as of December 31, 2025, primarily due to investments in production infrastructure for respiratory drug development[38] - Inventory decreased by 22.2% from RMB 47.2 million as of December 31, 2024, to RMB 36.7 million as of December 31, 2025, mainly due to a reduction in customer orders for the CF017 product[39] - Trade receivables surged from RMB 27.1 million as of December 31, 2024, to RMB 159.4 million as of December 31, 2025, attributed to longer settlement cycles and higher sales concentration in Q4 2025[40] - The trade receivables turnover days increased significantly from 9 days in 2024 to 79 days in 2025, reflecting changes in credit terms offered to distributors[41] - Cash and cash equivalents rose dramatically from RMB 81.9 million as of December 31, 2024, to RMB 414.9 million as of December 31, 2025, primarily due to net proceeds from a global offering[45] - Restricted cash and time deposits increased by 49.0% from RMB 5.1 million as of December 31, 2024, to RMB 7.6 million as of December 31, 2025, due to additional collateral deposits for procurement and construction obligations[44] - The company's trade payables and notes payable remained stable at RMB 20.6 million as of December 31, 2024, and RMB 21.4 million as of December 31, 2025[46] - The trade payables turnover days decreased from 75 days in 2024 to 73 days in 2025, indicating improved efficiency in managing payables[46] - Other payables and accrued expenses decreased by 38.0% from RMB 204.1 million as of December 31, 2024, to RMB 126.5 million as of December 31, 2025, primarily due to optimization of sales and distribution networks[47] - Cash and cash equivalents reached RMB 414.9 million as of December 31, 2025, with total current assets net value approximately RMB 696.2 million[48] - Interest-bearing borrowings increased from RMB 73.8 million as of December 31, 2024, to RMB 142.3 million as of December 31, 2025, mainly to support operational funding[51] - Capital expenditures decreased by 59.8% from RMB 174.0 million in 2024 to RMB 70.0 million in 2025, due to the completion of major construction projects[52] - The current ratio improved significantly to 4.59 as of December 31, 2025, compared to 1.88 as of December 31, 2024[55] - The company had no significant asset pledges as of December 31, 2025[58] - The company held approximately RMB 325.4 million in cash and bank balances denominated in USD as of December 31, 2025, an increase from RMB 4.3 million as of December 31, 2024[63] Corporate Governance and Compliance - The company has complied with the corporate governance code and maintained high standards of corporate governance since its listing on October 8, 2025[115] - The audit committee, consisting of three independent non-executive directors, reviewed the consolidated financial statements for the year ending December 31, 2025, with no significant changes in accounting policies[119] - The board of directors includes the chairman, executive directors, and independent non-executive directors[126] - The group did not recommend any dividend for the year ended December 31, 2025, consistent with the previous year[92] - The company has not identified any significant changes in the planned use of the net proceeds from the global offering[125] Future Outlook - The board maintains cautious yet firm confidence in the group's prospects for 2026, anticipating it to be a key year for growth and structural upgrades[67] - The domestic business is expected to improve visibility with the completion of brand volume under the VBP update plan and strategic partnerships with companies like Jiuzhoutong and JD Health[68] - The company aims to reduce reliance on a single product cycle and achieve more balanced growth through stable overseas deliveries and clinical advancements in its innovation pipeline[69]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 本公司長期專注於呼吸及鼻科領域的研發與生產，依託其在吸入製劑領域具備全 球競爭力的技術平臺，持續推進創新藥的研發與升級，已構建覆蓋過敏性鼻炎、 慢性鼻竇炎、哮喘及慢性阻塞性肺疾病等疾病的產品管線，形成了涵蓋單方與複 方藥物、貫穿全年齡段及全病程週期的全面管理體系。公司通過吸入途徑實現小 分子藥物、小核酸藥物等分子藥物的遞送，借助其在細胞與基因層面的作用機 制，探索更優的療效－安全性平衡，標誌著公司由複雜製劑向源頭創新藥轉型的 關鍵進展。該模式不僅將治療領域拓展至呼吸系統、中樞神經系統等全球範圍內 臨床需求未獲充分滿足的重症疾病，同時通過局部給藥策略優化免疫調控效應， 構建了「吸入製劑局部遞送+細胞靶向遞送+基因╱蛋白調控」的協同創新路徑。 CF PharmTech, Inc. 長風藥業股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2652） 自願公告 與京東健康簽署戰略合作 本公 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 CF PharmTech, Inc. 長風藥業股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2652） 內幕消息 盈利預警 本公告乃由長風藥業股份有限公司（「本公司」，連同其附屬公司統稱「本集團」）根 據香港聯合交易所有限公司（「聯交所」）證券上市規則（「上市規則」）第13.09(2)(a) 條以及香港法例第571章證券及期貨條例第XIVA部項下的內幕消息條文（定義見 上市規則）作出。 本公司董事會（「董事會」）謹此通知本公司股東（「股東」）及潛在投資者，基於對 本集團未經審核綜合管理賬目的初步審閱以及董事會目前所得資料，本集團預期 錄得(i) 2025年收入介乎人民幣410.0百萬元至人民幣450.0百萬元，而於2024年則 錄得約人民幣607.75百萬元之收入；(ii)根據國際財務報告準則(IFRS)會計準則， 2025年股東應佔溢利介乎人民幣2.0百萬元至人民幣3.0百萬元 ...

長風藥業股份有限公司（「本公司」）董事會（「董事會」）謹此宣佈，本公司將於 2026年3月30日（星期一）舉行董事會會議，藉以（其中包括）考慮並批准本公司及 其附屬公司截至2025年12月31日止之年度業績及其刊發，並考慮派發末期股息之 建議（如有），以及處理其他事項。 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2652） 董事會會議召開日期 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 CF PharmTech, Inc. 長風藥業股份有限公司 承董事會命 CF PharmTech, Inc. 長風藥業股份有限公司 董事長、執行董事兼首席執行官 梁文青博士 於本公告日期，董事會包括執行董事梁文青博士、李勵博士、李旗博士及朱玉玉 女士，非執行董事陳鵬輝先生、蔡磊先生及易華博士，及獨立非執行董事金堅博 士、王麗娟女士、魏士榮先生及葉耘開先生。 香港，2026年3月18日 ...

Group 1 - Zhipu AI (02513) saw a price increase of over 10% during trading, currently up 7.4%, following the announcement of its first closed-source model GLM-5-Turbo and a 20% price hike for its new model API [1] - Capital Airport (00694) dropped over 4% after JPMorgan downgraded its investment rating from "Neutral" to "Underweight" and cut the target price by 40% to HKD 1.8, citing structural challenges and potential selling pressure from being removed from the Hong Kong Stock Connect list [1] - Cloudwalk Technology (02670) rose over 7% after signing a strategic cooperation agreement with SF Express to define new standards for building delivery [1] Group 2 - Yiming Anke-B (01541) increased by over 8% after receiving approval for its II phase clinical study of IMM0306 for treating Primary Membranous Nephropathy [2] - WanGuo Data-SW (09698) surged over 12.6% after reporting a net revenue of RMB 11.4323 billion (USD 1.6348 billion) for the year, a 10.8% year-on-year increase, with adjusted EBITDA also up by 10.8% [2] - Automotive stocks collectively fell, with Li Auto-W (02015) down 6.24%, Xpeng Motors-W (09868) down 4.35%, and Great Wall Motors (02333) down 2.64%, amid warnings from multiple CEOs about rising chip costs [2] Group 3 - Smoore International (06969) opened slightly higher but fell 15.21% after reporting a revenue of approximately RMB 14.256 billion for 2025, a 20.8% increase, but a net profit decline of 18.5% [3] - China Cosco Shipping Energy Transportation (01138) rose 5.39% as reports indicated significant impacts on the tanker and energy markets due to ongoing Middle East conflicts [3] Group 4 - China Oriental Education (00667) increased by 6.57% after reporting a revenue of RMB 4.616 billion for 2025, a 12.1% year-on-year increase, with net profit up 47.5% [4] - Changfeng Pharmaceutical (02652) surged over 21%, currently up 9.99%, after announcing the acceptance of its IND application for a new inhalation powder for treating pulmonary arterial hypertension [4] Group 5 - Swarmer (SWMR.US) debuted on the US stock market with a staggering opening price increase of 315.4%, currently up 520%, focusing on AI-driven drone swarm control systems [5] - 36Kr (KRKR.US) rose 37.39% after reporting a total revenue of RMB 227 million for 2025, with a gross margin increase to 58% and a net profit of approximately RMB 11.42 million [5] - Space-related stocks saw active trading, with Rocket Lab (RKLB.US) up 10.21% and Planet Labs PBC (PL.US) up 10.08% [5] Group 6 - Solaris Energy Infrastructure (SEI.US) rose 10.88% after announcing agreements worth USD 620 million to add approximately 900 MW of gas turbine capacity between 2026 and 2029 [7] - Uber (UBER.US) increased by 4.19% following a partnership with NVIDIA to deploy autonomous taxi fleets in major US cities by 2027 [8] - Aiko Solar (CSIQ.US) rose 1.94% after announcing a supply agreement for a 500 MW energy storage project [8] - Atour (ATAT.US) saw a price increase of 5.98% after reporting a net revenue of approximately RMB 2.788 billion for Q4 2025, a 33.8% year-on-year increase [8]

Market Updates - JD Health (06618) rose over 4.5% following a strategic partnership announcement with leading medical device brand Yuyue Medical [1] - Kangfang Biopharma (09926) increased by over 5.7% after receiving NMPA clinical trial approval for its novel tri-specific antibody drug AK150 for treating advanced malignant solid tumors [1] - Yunfeng Financial (00376) saw a significant rise of 14.18%, with a previous day increase of over 10%, amid a temporary suspension announcement related to a major stock price surge [1] - Steel stocks collectively declined, with Asia Pacific Resources (01104) down 7.59% and Maanshan Iron & Steel (00323) down 7.28% [1] Earnings Warnings and Gains - Jiuyuan Group (00827) fell over 20% after issuing a profit warning, projecting a net loss of approximately RMB 709 million for the year ending December 31, 2025, an increase from a loss of RMB 505 million in 2024 [2] - Changfeng Pharmaceutical (02652) surged nearly 43% after announcing that its inhalation powder ICF001 for treating pulmonary arterial hypertension has received NMPA acceptance for clinical trial application [2] - Yicheng Industrial (01596) rose over 76% after announcing a projected net profit of approximately RMB 334 million for the year ending December 31, 2025, compared to a net loss of RMB 57.7 million in 2024 [3] - Akeso Biopharma (09939) increased by over 10.7% following a strategic cooperation agreement with Funo Pharmaceuticals to develop a new cosmetic product [3] Other Notable Movements - Soundon Technology (02495) rose over 5% after projecting a net profit of no less than RMB 120 million for the year ending December 31, 2025, compared to a net loss of RMB 481 million in 2024 [4] - Starry Chain Group (00399) saw an increase of 18.52% after announcing a memorandum of understanding with Newbridge Acquisition Limited for potential acquisition opportunities [4] US Market Highlights - Tencent Holdings (ADR) (TCEHY.US) rose 1.11% as it welcomed Apple's adjustment of App Store commission policies in China [5] - Meta (META.US) fell 3.83%, marking its largest intraday drop since March 6, due to delays in the release of its new AI model [5] - Ulta Beauty (ULTA.US) dropped 14.24% despite strong same-store sales growth, as fourth-quarter profits fell short of expectations [5] - Bitcoin rose over 5% to $73,764, while Ethereum increased over 6.5% to $2,201.41, reflecting a positive trend in the cryptocurrency sector [6]

CF PharmTech, Inc. 長風藥業股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2652） 自願公告 NMPA受理ICF001的IND申請 本公告乃由長風藥業股份有限公司（「本公司」，連同其附屬公司統稱「本集團」）自 願作出，以知會股東及潛在投資者有關本集團之最新研發進展。 引言 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 本公司董事（「董事」）會（「董事會」）欣然宣佈，本公司自主研發的吸入粉霧劑候 選藥物ICF001（「產品」）之新藥臨床試驗（「IND」）申請（「該申請」）已獲中華人民 共和國國家藥品監督管理局（「NMPA」）受理。茲公告相關資訊如下： 產品名稱 : ICF001（吸入粉霧劑） 受理號 : CXHL2600306/CXHL2600307/CXHL2600308/ CXHL2600309/CXHL2600310/CXHL2600311 申請人 : 長風蘇粵藥業（廣州）有限公司 （本公司之附屬公司 ...

Major Events - Heng Rui Medicine (01276) has received the clinical trial approval notice for Adalimumab injection [1] - Anjoy Foods (02648) plans to increase capital by 120 million yuan to its subsidiary in Henan [1] - Xuan Zhu Bio-B (02575) has been included in the Hong Kong Stock Connect stock list [1] - Peijie Biopharma-B (02565) reports one-month clinical observation results from the first human trial of its next-generation GLP-1 (CR059) [1] - Changfeng Pharmaceutical (02652) has been included in the Hong Kong Stock Connect eligible securities list [1] - Binhai Investment (02886) has secured financing of up to 45 million USD and 173 million yuan in various currency term loans [1] - He Yu-B (02256) reports results from the global Phase III MANEUVER study of Beijiemai® published in The Lancet [1] Operating Performance - Yuexiu Property (00123) reported a cumulative contract sales amount of approximately 7.106 billion yuan in the first two months [1] - Mengniu Dairy (02319) expects annual profit attributable to shareholders to be approximately 1.4 billion to 1.6 billion yuan [1] - Dongfeng Motor Group (00489) reported cumulative automobile sales of 228,518 units in the first two months, a year-on-year increase of approximately 1.2% [1] - Shangmei Co. (02145) issued a profit warning, expecting a profit of approximately 1.14 billion to 1.16 billion yuan for 2025, a year-on-year increase of approximately 41.9% to 44.4% [1] - Longfor Group (00960) achieved a total contract sales amount of 4.45 billion yuan in the first two months [1] - ZTE Corporation (00763) reported a net profit attributable to shareholders of 5.618 billion yuan for 2025, a year-on-year decrease of 33.32% [1] - Huishang Bank (03698) issued a positive profit forecast, expecting a net profit of approximately 16.93 billion yuan for 2025, a year-on-year increase of approximately 6.3% [1] - Sun Hung Kai Properties (00086) issued a profit warning, expecting a consolidated profit attributable to shareholders of no less than 1.5 billion HKD for 2025 [1]